Cure My Disease

Don't miss your cure!

 Log in / Sign up

Grip strength may reveal hidden liver risks

NCT ID NCT07116096

Knowledge-focused Sponsor: Shanxi Provincial People's Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether handgrip strength—a simple measure of muscle function—can help predict changes in blood flow through the liver's main vein in people with cirrhosis. Researchers will measure blood pressure and flow in the portal vein and nearby veins before and after a handgrip test, using three different methods. The goal is to find a non-invasive way to assess the risk of complications like variceal bleeding. About 120 adults with cirrhosis will take part.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 120 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2025

Expected to finish

Aug 2026

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults aged ≥18 years old * Clinically diagnosed with liver cirrhosis * Endoscopic observation to determine the presence of esophagogastric varices * Only eligible for the portal vein pressure measurement group if there are no signs of variceal bleeding for at least 14 days * Participant or guardian is capable of comprehending the study protocol, willing to participate, and able to provide written informed consent Exclusion Criteria: * Severe congestive heart failure, or severe untreated valvular heart disease * Moderate to severe pulmonary hypertension * Uncontrolled systemic infection * Lesions (e.g., cysts) or tumors in the liver parenchyma that preclude TIPS creation * Overt hepatic encephalopathy * Unrelieved biliary obstruction * Child-Pugh score \> 13 * MELD score \> 18 * INR \> 5 * Platelet count \< 20 ×109/mm3 * No gastrointestinal bleeding (suitable for the ultrasound examination group and the endoscopic ultrasonography group) * Participants who had undergone hand or wrist surgery within the previous 3 months or were unable to hold the dynamometer with the testing hand were excluded from the study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Liver cirrhosis are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cirrhosis of liver portal hypertension

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Liver cirrhosis Portal hypertension

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Shanxi Provincial People's Hospital

    RECRUITING

    Taiyuan, Shanxi, 030012, China

  • The First Affiliated Hospital of Henan University of Science and Technology

    RECRUITING

    Luoyang, Henan, 471003, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.